News

Researchers Identify Cancer-Associated Fibroblasts Driving Aggressive Thyroid Cancer Progression

Research Advances /

A study has identified specific cancer-associated fibroblasts (CAFs) as key drivers of invasion and progression in aggressive Thyroid Cancer. By mapping the tumor stroma, researchers found that these cells create a microenvironment that promotes metastasis and resistance to treatment. The researcher used single-cell sequencing and spatial transcriptomics to analyze 81 patient samples, comparing slow-growing tumors with […]

Researchers Identify Cancer-Associated Fibroblasts Driving Aggressive Thyroid Cancer Progression Read More »

Namodenoson Achieves Primary Safety Goal in Phase 2a Trial for Advanced Pancreatic Cancer

Clinical Trails /

Can-Fite BioPharma announced that its Phase 2a trial of namodenoson (CF102) met its primary safety goal in patients with advanced Pancreatic Ductal Adenocarcinoma (PDAC). The study included 20 heavily pretreated patients whose disease had progressed after prior therapies. Namodenoson was well tolerated, with no new safety concerns, and its safety profile was consistent with previous

Namodenoson Achieves Primary Safety Goal in Phase 2a Trial for Advanced Pancreatic Cancer Read More »

Early ctDNA Testing Offers Rapid Prediction of Immunotherapy Response in Melanoma

Precision Medicine /

A new study shows that circulating tumor DNA (ctDNA) can predict the effectiveness of immunotherapy in advanced Melanoma just 3–4 weeks after treatment starts—much faster than standard scans. Using the tumor-informed Signatera assay, doctors can track tumor DNA fragments in the blood to monitor response in real time. Early changes in ctDNA were strongly linked

Early ctDNA Testing Offers Rapid Prediction of Immunotherapy Response in Melanoma Read More »

FDA Approves Teclistamab Plus Daratumumab for Relapsed or Refractory Multiple Myeloma Following MajesTEC-3 trial Results

Drug Approvals /

The U.S. Food and Drug Administration has granted traditional approval to teclistamab (Tecvayli) in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro) for adults with relapsed or refractory Multiple Myeloma who have received at least one prior treatment. The agency also converted teclistamab as a single therapy from accelerated approval to full approval. The decision is

FDA Approves Teclistamab Plus Daratumumab for Relapsed or Refractory Multiple Myeloma Following MajesTEC-3 trial Results Read More »

BREAKWATER trial Establishes New First-Line Targeted Therapy Standard for Metastatic Colorectal Cancer with BRAF V600E mutation

Clinical Trails /

Results from the Phase 3 BREAKWATER trial suggest a new first-line treatment approach for metastatic colorectal cancer with the BRAF V600E mutation. Using targeted therapy early can significantly improve outcomes for patients with this aggressive form of cancer. The treatment combines encorafenib (Braftovi), cetuximab (Erbitux), and fluorouracil-based chemotherapy. In the trial, the combination achieved an

BREAKWATER trial Establishes New First-Line Targeted Therapy Standard for Metastatic Colorectal Cancer with BRAF V600E mutation Read More »

Researchers Identify Immune-Evasion Mechanism Driving Metastasis in Triple-Negative Breast Cancer

Research Advances /

Researchers have discovered a way that metastatic tumor cells avoid the immune system in Triple-Negative Breast Cancer (TNBC). The study, led by Judith Agudo and published in Nature, describes how cancer cells traveling through the body can hide from immune attack and form tumors in organs such as the lungs, liver, and brain. Using a

Researchers Identify Immune-Evasion Mechanism Driving Metastasis in Triple-Negative Breast Cancer Read More »

U.S. Food and Drug Administration Approves Pembrolizumab for Platinum-Resistant Ovarian Cancer Following KEYNOTE-B96 trial Results

Drug Approvals /

The U.S. U.S. Food and Drug Administration approved pembrolizumab (Keytruda) and pembrolizumab/berahyaluronidase alfapmph (Keytruda Qlex) for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The treatment is used together with weekly paclitaxel, with or without bevacizumab, for patients who have already received one or two prior systemic therapies. Patients must have tumors

U.S. Food and Drug Administration Approves Pembrolizumab for Platinum-Resistant Ovarian Cancer Following KEYNOTE-B96 trial Results Read More »

Fingolimod Shows Potential as a Repurposed Therapy for Adrenocortical Carcinoma

Rare Cancers /

A new study examined whether Fingolimod, a drug originally approved to treat Multiple Sclerosis, could be repurposed to treat Adrenocortical Carcinoma. Researchers focused on the sphingolipid metabolic pathway and found that high activity of genes involved in producing Sphingosine1Phosphate (S1P) is linked to more advanced disease, more aggressive tumors, and poorer survival in patients with

Fingolimod Shows Potential as a Repurposed Therapy for Adrenocortical Carcinoma Read More »

Celastrol Shows Promising Anticancer Activity Against Adrenocortical Carcinoma

Rare Cancers /

A new study explored the anticancer effects of Celastrol, a bioactive compound from traditional Chinese medicine, against Adrenocortical Carcinoma using the H295R cancer cell line. Researchers found that Celastrol strongly reduced the survival of cancer cells in a dose-dependent manner, with an IC50 of about 1.63 µM. The compound mainly caused apoptosis, a form of

Celastrol Shows Promising Anticancer Activity Against Adrenocortical Carcinoma Read More »

New Study Identifies Secreted Phosphoprotein 1–CXCL12 Pathway as Key Driver of Immunotherapy Resistance in Colorectal Cancer Liver Metastasis

Research Advances /

A new study found that a protein called Secreted Phosphoprotein 1 (SPP1) plays an important role in helping colorectal cancer spread to the liver and resist immunotherapy. Researchers discovered that SPP1 levels are much higher in liver metastases than in primary colorectal tumors. Patients with high levels of SPP1 in their blood tend to have

New Study Identifies Secreted Phosphoprotein 1–CXCL12 Pathway as Key Driver of Immunotherapy Resistance in Colorectal Cancer Liver Metastasis Read More »